Anaplastic Large Cell Lymphoma Clinical Trial
Official title:
The Safety and Clinical Efficacy of Human CD7 CAR-T Cell Therapy for Patients With Relapsed/Refractory CD7 Positive T Cell Hematological Maliganacies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
Status | Recruiting |
Enrollment | 4 |
Est. completion date | November 1, 2024 |
Est. primary completion date | August 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 70 Years |
Eligibility | Inclusion criteria 1. Fourteen to 70 Years Old, Male and female; 2. Expected survival > 12 weeks; ECOG score 0-2; 3. Confirmed diagnosis of acute T cell leukemia and screened for CD7 positive,including following conditions:a. Patients who do not get a CR with =2 prior induction therapy b. Those who achieves CR, but have a early relapse(<12months),or a late relapse (>=12months) failing to acheive a CR after re-induction chemotherapy c. For any Patiens failed ASCT/allo-SCT 4. Relapsed and refractory patients with diagnosis of CD7 positive T cell lymphoma have had=2 prior lines of therapy,who do not acheive at least a PR, or have a relapse including:a. Peripheral T cell lymphoma NOS, or b.Angioimmunoblastic T cell lymphoma,or c. Anaplastic large cell lymphoma c.Disease can be assessed(BM or CT scan) 5. Confirmed T lymphoblatic lymphoma:a. Patients who do not get a PR with =2 induction chemotherapy or a CR with = 4 induction chemotherapy b. Relapsed patients failing to acheive a CR after 1 line salvage chemotherapy c. For any Patiens failed ASCT/allo-SCT d.Disease can be assessed(BM or CT scan) 6. The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators; 7. Liver, kidney and cardiopulmonary functions meet the following requirements: a. Ccr=60mL/min(Cockcroft Gault) b. Left ventricular ejection fraction >50%; c.Baseline oxygen saturation>92%; d. Total bilirubin = 1.5×ULN; e. ALT and AST= 3×ULN; 8. Able to understand and sign the Informed Consent Exclusion Criteria: 1. Malignant tumors other than T cell malignancies within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection; 2. Uncontrolled infection including bacteral or virus or fugal disease;patients with positive HBsAg or HBcAb and positive peripheral blood HBV DNA titer detection ;HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; syphilis positive; 3. Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening),myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification = III), need drug therapy of severe arrhythmia,liver, kidney, or metabolic disease; 4. Any uncontrolled disease may affect entry 5. Current or history of CNS involvement by malignancy.Known history or presence of clinically relevant central nervous system (CNS) pathology.Patients with a known history or prior diagnosis other immunologic or inflammatory disease affecting the CNS (such as epilepsy) 6. Patients who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion; 7. Subjects treated with anti-PD1 or anti-PDL1 therapies within 3months before enrollment 8. Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pr egnancy within 1 year after cell transfusion; 9. Active or uncontrollable infection requiring systemic therapy Received CAR-T treatment or other gene therapies before enrollment; 10. Kown be allergic to anti-TRBC1 CAR-T cells or drugs(Fludarabine or Cyclophophamide) 11. The investigators consider other conditions unsuitable for enrollment. 12. Patients who may not be able to sign the Informed Consent due to disease,or who do not understand or unwillingness or inability to comply with research requirements |
Country | Name | City | State |
---|---|---|---|
China | Xianmin General Song | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Immunogenicity of CAR-T cells | Using flow cytometry to detect whether anti-car antibodies are contained in serum of patients receiving CAR-T cells infusion,and to evaluate the number of participants with antibodies | 2 years post infusion | |
Primary | Incidence of Treatment-Emergent Adverse Events | The occurence of study related adverse effects defined by NCI CTCAE5.0 | 28 days post infusion | |
Secondary | CAR-T cell expansion | Using flow cytometry to reveal cell surface expression of the CAR protein on T cells;and using quantitative polymerase chain reaction to detect DNA copies of the transgene irrespective of gene expression(per ug DNA) to evaluate anti-CD7 CAR-T cell expansion after infusion | 2 years post infusion | |
Secondary | CAR-T cell persistence | Using flow cytometry to reveal cell surface expression of the CAR protein on T cells;and using quantitative polymerase chain reaction to detect DNA copies of the transgene irrespective of gene expression(per ug DNA) to evaluate anti-CD7 CAR-T cell persistence after infusion | 2 years post infusion | |
Secondary | Number of CD7+ lymphocytes of peripheral blood | To evaluate CD7 positive cells of peripheral blood after infusion | 2 years post infusion | |
Secondary | Total response rate (ORR) after administration | CR+CRi for T-ALL ;CR+PR for T cell lyphoma and T lymphoblastic lymphoma | 3 months post infusion | |
Secondary | Duration of remission (DOR) after administration | Duration of remission (DOR) after administration | 2 years post infusion | |
Secondary | Overall survival(OS) after administration | Overall Survival (OS)after administration | 2 years post infusion | |
Secondary | Progression Free Survival (PFS) after administration | Progression Free Survival (PFS) after administration | 2 years post infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT02168140 -
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT01943682 -
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
|
Phase 1 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00003196 -
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
|
N/A | |
Terminated |
NCT01678443 -
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Terminated |
NCT03947255 -
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
|
Phase 2 | |
Terminated |
NCT01408043 -
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT01466881 -
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT00608361 -
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00131937 -
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00278382 -
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00098891 -
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01254578 -
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
|
Phase 1 | |
Recruiting |
NCT03443128 -
Vinorelbine for Recurrent ALCL-2017
|
Phase 2 | |
Completed |
NCT03397953 -
Vinorelbine for Recurrent ACLC
|
Phase 2 |